Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry

Version 1 : Received: 18 June 2021 / Approved: 21 June 2021 / Online: 21 June 2021 (11:31:02 CEST)

A peer-reviewed article of this Preprint also exists.

Chiangjong, W.; Bhakdi, S.C.; Woramongkolchai, N.; Vanichapol, T.; Pongsakul, N.; Hongeng, S.; Chutipongtanate, S. Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry. Cancers 2021, 13, 3775. Chiangjong, W.; Bhakdi, S.C.; Woramongkolchai, N.; Vanichapol, T.; Pongsakul, N.; Hongeng, S.; Chutipongtanate, S. Cell-Main Spectra Profile Screening Technique in Simulation of Circulating Tumour Cells Using MALDI-TOF Mass Spectrometry. Cancers 2021, 13, 3775.

Journal reference: Cancers 2021, 13, 3775
DOI: 10.3390/cancers13153775

Abstract

Circulating atypical cells (CAC) are released from a primary tumour site into peripheral blood and are indicators of cancer metastasis. CAC occur at very low frequency in circulating blood, and their detection remains challenging. Moreover, white blood cells (WBC) are the major contaminant in enriched CAC samples. Here, we developed matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) as a novel CAC characterization platform. Main spectra profiles (MSP) of normal and cancer cells were generated by MALDI-TOF MS, and a cell-main spectra database was then compiled and analysed using the MALDI Biotyper software. Logarithmic scores accurately predicted distinct cell types. The feasibility of this workflow was then validated using simulated samples, which were prepared by 5,000 WBC of three healthy individuals spiked with varying numbers (3, 6, 12, 25, 50 and 100) of lung, colon, or prostate cancer cells. MALDI-TOF MS was able to detect cancer cells down to six cells over the background noise of 5,000 WBC with significantly higher predictive scores as compared to WBC alone. Further development of cell-MSP database to cover all cancer types sourced from cell lines and patient tumours may enable the use of MALDI-TOF MS as a cancer-screening platform in clinical settings in the future.

Keywords

Cell main spectra; Circulating tumour cell; MALDI-TOF; Method development

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.